西妥昔单抗联合FOLFOX化疗治疗转移性结直肠癌的临床研究

Clinical Research of Cetuximab Combined with FOLFOX Chemotherapy for Treating Metastatic Colorectal Cancer

关键词:  西妥昔单抗  FOLFOX  转移性结直肠癌

Key words:  cetuximab  FOLFOX  metastatic colorectal cancer

摘要:

目的 观察西妥昔单抗联合FOLFOX化疗治疗转移性结直肠癌(MCRC)的近期疗效及不良反应。方法 48例确诊为MCRC患者为研究对象。西妥昔单抗每周给药，首剂负荷量为400 mg·m^-2，维持量为250 mg·m^-2；联合方案：奥沙利铂85 mg·m^-2+5-氟尿嘧啶600 mg·m^-2+亚叶酸钙200 mg·m^-2，2周为一个周期。完成两个周期的化疗以后，评价疗效，观察中位至疾病进展时间和不良反应。结果 完全缓解0例，部分缓解39例，疾病稳定9例，疾病进展0例，总有效率81.3%，疾病控制率100.0%，中位至疾病进展时间是9个月。不良反应主要为Ⅰ~Ⅱ级。结论 西妥昔单抗联合FOLFOX的化疗方案治疗MCRC可获得较高有效率，延长了疾病进展时间，改善了患者的生活质量，值得临床推广应用。

Abstract:

OBJECTIVE To observe the recent efficacy and toxicity of cetuximab combined FOLFOX chemotherapy for treating metastatic colorectal cancer (MCRC). METHODS Forty-eight cases of patients with MCRC were studied. Cetuximab was administered weekly, the first loading dose was 400 mg·m^-2, maintenance dose was 250 mg·m^-2. Joint programme: oxaliplatin 85 mg·m^-2+5-fluorouracil 600 mg·m^-2+leucovorin 200 mg·m^-2, 2 weeks as a cycle. After 2 cycles of chemotherapy, recent efficacy was evaluated, the TTP and toxicity were observed. RESULTS CR 0 case, PR 39 cases, SD 9 cases, PD 0 case, the total effective rate was 81.3%, the disease control rate was 100.0%, the TTP was 9 months. The toxicity was mainly Ⅰ-Ⅱ grade. CONCLUSION Cetuximab combined with FOLFOX chemotherapy for treating MCRC can get higher efficiency, longer TTP and can improve the quality of patient’s life. It is worthy of clinical application.